Buprenorphine Detoxification - BBDVI - 19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00000237
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : August 17, 2005
University of Vermont
Information provided by:
National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is to examine the long-term efficacy of alternate-day dosing schedules in promoting treatment compliance in the absence of confounding behavioral contingencies.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Drug: Buprenorphine Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 0 participants
Primary Purpose: Treatment
Official Title: Buprenorphine Detoxification - BBDVI
Study Start Date : May 1997

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Drug use
  2. Retention
  3. Weeks abstinent
  4. Weeks continuous abstinence
  5. Overall treatment outcome
  6. Opioid dependence and psychiatric status

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00000237

United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of Vermont
Principal Investigator: Warren Bickel, Ph.D. University of Vermont Identifier: NCT00000237     History of Changes
Other Study ID Numbers: NIDA-06969-19
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: August 17, 2005
Last Verified: May 1997

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists